Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALDP001 in Seasonal Allergic Rhinitis
NCT07219849Phase 2Recruiting
- Sponsor
- Alixer Nexgen Therapeutics
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alcaftadine in seasonal allergic rhinitis (SAR), sponsored by Alixer Nexgen Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
alcaftadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07219849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219849.